'I am hopeful these findings are a wake-up call for FDA to reform its practices and a call to action to my congressional colleagues to continue oversight of the pharmaceutical industry to ensure they don't put profits over patients,' says repmaloney
"This report documents the atypical FDA review process and corporate greed that preceded FDA's controversial decision to grant accelerated approval to Aduhelm."
The panel also found that Biogen and the FDA closely collaborated on a document written for outside advisers during the approval process, with at least one paragraph of the company's submission authored by agency officials. "This report documents the atypical FDA review process and corporate greed that preceded FDA's controversial decision to grant accelerated approval to Aduhelm," outgoing House Energy and Commerce Committee Chair Frank Pallone said in a;“NEW: Chairman @FrankPallone and House Oversight Chair @RepMaloney release report on the controversial review, approval, and pricing of Biogen;’s Alzheimer;’s drug Aduhelm.
"I am hopeful these findings are a wake-up call for FDA to reform its practices and a call to action to my congressional colleagues to continue oversight of the pharmaceutical industry to ensure they don't put profits over patients," she added.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
House Dems Say FDA 'Inappropriately Collaborated' With Biogen on New Alzheimer's Drug'I am hopeful these findings are a wake-up call for FDA to reform its practices and a call to action to my congressional colleagues to continue oversight of the pharmaceutical industry to ensure they don't put profits over patients,' said Rep. Carolyn Maloney.
Leer más »
Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drugThe U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was 'rife with irregularities,' a congressional report showed on Thursday.
Leer más »
Congressional probe faults FDA on Biogen Alzheimer's drug approvalAn 18-month congressional investigation found the FDA didn't follow its own guidance and inappropriately collaborated with drugmaker Biogen before the approval of a controversial Alzheimer's drug last year.
Leer más »
Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drugThe U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was 'rife with irregularities,' a congressional report showed on Thursday. The FDA's interactions with Biogen were 'atypical' and did not follow the agency's documentation protocol, according to a staff report on the findings of an 18-month investigation conducted by two House of Representatives committees into the drug's regulatory review, approval, pricing, and marketing. The FDA approved Aduhelm in June 2021 under an accelerated approval pathway over the objections of its panel of outside advisers, who did not believe data definitively proved the drug's benefit to patients.
Leer más »
FDA broke own protocols in approving Biogen Alzheimer’s drug, congressional report saysThe FDA failed to adhere to its own guidance and internal practices during the approval process for Biogen’s Alzheimer’s drug, which was “rife with irregularities,” a congressional report says.
Leer más »
FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer’s DrugBreaking: The FDA inappropriately collaborated with Biogen before approving its Alzheimer's drug Aduhelm, a report by House Democrats found
Leer más »